Zhigang R. Guo

1 WenYuan Road
Nanjing, 210023, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 159 publications

Cascading Attrition of In Vivo CAR-T Therapy: From Systemic Delivery Failure to Functional Collapse.

Cascading Attrition of In Vivo CAR-T Therapy: From Systemic Delivery Failure to Functional Collapse.

Journal: Critical reviews in oncology/hematology

Published: May 26, 2026

A potent anti-CD47 antibody decoupling anti-tumor efficacy from hematotoxicity.

A potent anti-CD47 antibody decoupling anti-tumor efficacy from hematotoxicity.

Journal: International immunopharmacology

Published: May 20, 2026

Universal CAR-T cell therapy: mechanisms and evasion strategies of bidirectional immune rejection.

Universal CAR-T cell therapy: mechanisms and evasion strategies of bidirectional immune rejection.

Journal: Biochimica et biophysica acta. Reviews on cancer

Published: April 30, 2026

Next-Generation CAR-T Therapies: From Personalized Anticancer Drugs to Broadly Applicable Disease-Modifying Treatments.

Next-Generation CAR-T Therapies: From Personalized Anticancer Drugs to Broadly Applicable Disease-Modifying Treatments.

Journal: Transplantation and cellular therapy

Published: April 03, 2026

CAR-T cell therapy for autoimmune diseases: from immune suppression to immune resetting.

CAR-T cell therapy for autoimmune diseases: from immune suppression to immune resetting.

Journal: International immunopharmacology

Published: March 26, 2026

In Vivo Generation of CAR-T Cells: Current Obstacles, Strategic Solutions, and Clinical Translation.

In Vivo Generation of CAR-T Cells: Current Obstacles, Strategic Solutions, and Clinical Translation.

Journal: Critical reviews in oncology/hematology

Published: March 25, 2026

Correction: Nattokinase-driven remodeling of tumor microenvironment enhances the efficacy of MSLN-targeted CAR-T cell therapy in solid tumors.

Correction: Nattokinase-driven remodeling of tumor microenvironment enhances the efficacy of MSLN-targeted CAR-T cell therapy in solid tumors.

Journal: Cancer immunology, immunotherapy : CII

Published: March 18, 2026

A psychological network analysis of parental and peer support on children's football participation: the bridging role of self-efficacy.

A psychological network analysis of parental and peer support on children's football participation: the bridging role of self-efficacy.

Journal: Frontiers in psychology

Published: February 26, 2026

Macrophage PSRC1 attenuates atherosclerosis via extracellular vesicle-mediated MBD2 delivery to induce PCSK9 promoter methylation in hepatocytes.

Macrophage PSRC1 attenuates atherosclerosis via extracellular vesicle-mediated MBD2 delivery to induce PCSK9 promoter methylation in hepatocytes.

Journal: Cell & bioscience

Published: February 04, 2026

Erythrocyte membrane-liposome coating sustains circulation stability and targeted tumor therapy of CAR-T cells.

Erythrocyte membrane-liposome coating sustains circulation stability and targeted tumor therapy of CAR-T cells.

Journal: Frontiers in immunology

Published: January 29, 2026

Mechanical preconditioning by shear stress enhances memory formation and anti-tumor function of CAR-T cells.

Mechanical preconditioning by shear stress enhances memory formation and anti-tumor function of CAR-T cells.

Journal: Cancer immunology, immunotherapy : CII

Published: January 12, 2026

HDAC9 promotes atherosclerosis by suppressing CYP7A1 and impairing hepatic cholesterol excretion.

HDAC9 promotes atherosclerosis by suppressing CYP7A1 and impairing hepatic cholesterol excretion.

Journal: Clinical science (London, England : 1979)

Published: January 07, 2026

Showing 1-12 of 159

Last Updated: 09/26/2026